Clinical Trial Update: FX-322 in Adults With Stable Sensorineural Hearing Loss [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for FX-322 in adults with sensorineural hearing loss has completed; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Noise-induced Hearing Loss
• Sensorineural Hearing Loss
• Sudden Sensorineural Hearing Loss

Drugs mentioned

• FX-322

Snippet

Sponsor: Frequency Therapeutics | Conditions: Sensorineural Hearing Loss, Noise Induced Hearing Loss | Phase 2 | Status: COMPLETED | Results posted: 2023-04-27